Skyepharma slides as US group ends asthma drug deal – The Guardian


Stockopedia

Skyepharma slides as US group ends asthma drug deal
The Guardian
Shares in Skyepharma have fallen around 5% after another setback for its asthma treatment flutiform. The company has announced that Abbott Laboratories has
SkyePharma loses US partnerGrowthBusiness.co.uk
Abbot shelves interest in SkyePharma's FlutiformShareCast
SkyePharma says Abbott ends US Flutiform dealReuters
Wall Street Journal –Stockopedia
all 8 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *